Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today the commercial availability of a new test to assess a patient's viral load of cytomegalovirus (CMV). Physicians use information from the test to help them manage patients who have been diagnosed with CMV disease, specifically patients with an immune system that has been suppressed for solid organ transplantation. The test received premarket approval (PMA) from the U.S. Food and Drug Administration (FDA) in July 2012.
"With this new test, diagnostic laboratories now have a standardized, FDA-approved option for CMV viral load testing that addresses a key medical need for transplant patients," said Whitney Green, senior vice president, molecular diagnostics, for Roche Diagnostics Corporation. "There has been significant interest in the test from labs and the transplant community since the FDA approval, as it will provide physicians with clinically useful information to help them manage patients with CMV disease."
The real-time polymerase chain reaction (PCR)-based CMV test provides standardization of CMV viral load monitoring with traceability to the WHO International CMV standard. It is designed for use on Roche's fully automated COBAS® AmpliPrep/COBAS® TaqMan® System, an established platform for viral load monitoring of multiple infectious diseases that helps laboratories improve their workflow. The system can be combined with the cobas p 630 Instrument, which provides an integrated pre-analytical primary tube handling solution.
SOURCE Roche Diagnostics